Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Tianjin
Clinical trial register · China

Clinical Trials in Tianjin, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19224 matching records held by the registry are in this view. Synced 11 Nov 2026, 03:17 UTC
19224
Studies in scope
all four open statuses
11811
Recruiting now
open to new participants
2030
Lead sponsors
across recruiting studies
Top sites
Beijing 5586 Shanghai 3885 Guangzhou 3356 Hangzhou 1825 Wuhan 1342
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Institute of Hematology & Blood Diseases Hospital, China203 Tianjin Medical University Cancer Institute and Hospital170 Tianjin Medical University Second Hospital28 Tianjin Medical University24 Tianjin Medical University General Hospital19
Site location
Beijing5586 Shanghai3885 Guangzhou3356 Hangzhou1825 Wuhan1342
All 625 locations
Target enrolment
to

Trials with a site in Tianjin

937 of 19224 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Active, closed
Genmab
Phase 3
584
Guangzhou, Xi'an, Changchun, Hanzhou, Shanghai, Tianjin, Zhengzhou
2025-02-07
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
80
Tianjin
2025-02-05
Recruiting
BeOne Medicines
Phase 1
120
Guangzhou, Zhengzhou, Shanghai, Tianjin, Hangzhou
2025-02-04
By invitation
Laparoscopic Staging for Stage III Gastric Cancer
NCT07533825Gastric Cancer (GC), Gastric Adenocarcinoma
Tianjin Medical University Cancer Institute and Hospital
Not applicable
968
Tianjin
2025-02-01
Recruiting
Dose-attenuated IST and Hetrombopag in Elderly (≥65 Years) Patients With Severe Aplastic Anemia
NCT07010237Sever Aplastic Anaemia, Elderly (People Aged 65 or More), Immunosuppressive Treatment
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
65
Tianjin
2025-02-01
Not yet open
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 1/2
68
Fuzhou, Guangzhou, Zhengzhou, Nanchang, Tianjin, Kunming
2025-02
Not yet open
Tasly Pharmaceutical Group Co., Ltd
Phase 2
288
Tianjin
2025-01-31
Recruiting
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
NCT06564038Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Mantle-cell Lymphoma, Large B-cell Lymphoma
DrugsSurovatamig·Acalabrutinib·Vincristine·Doxorubicin
AstraZeneca
Phase 1/2
408
Beijing, Guangzhou, Jinan, Tianjin, Zhengzhou
2025-01-30
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Phase 1/2
29
Tianjin
2025-01-26
Active, closed
Nanjing Chia-tai Tianqing Pharmaceutical
Phase 2
24
Tianjin, Hangzhou
2025-01-23
Active, closed
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
41
Tianjin
2025-01-21
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
20
Tianjin
2025-01-20
Recruiting
A Clinical Study of NAD in the Treatment of Immune Thrombocytopenia
NCT06776510Immune Thrombocytopenia, Treatment
Institute of Hematology & Blood Diseases Hospital, China
Phase 1/2
20
Tianjin
2025-01-15
Recruiting
Shanghai Auzone Biological Technology Co., Ltd.
Phase 2
150
Beijing, Changsha, Chengdu, Nanjing, Tianjin
2025-01-13
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Phase 3
284
Tianjin
2025-01-10
Recruiting
CD (Suzhou) Biopharma Co., Ltd.
Phase 1
137
Tianjin
2025-01-08
By invitation
Oriental Neurosurgery Evidence-Based-Study Team
Not applicable
45
Tianjin
2025-01-08
Recruiting
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 1
163
Beijing, Zhengzhou, Changsha, Nanjing, Jinan, Shanghai, Tianjin
2025-01-08
Recruiting
CASI pharmaceuticals, Inc.
Phase 1/2
75
Tangshan, Zhengzhou, Nanchang, Jinan, Tianjin, Kunming
2025-01-03
Recruiting
TACS on High-inflammatory and Refractory Depression
NCT06812923Treatment Resistant Depression (TRD), Inflammation
Tianjin Anding Hospital
Not applicable
52
Tianjin
2025-01-01
Recruiting
Fudan University
Phase 2
165
Fuzhou, Shanghai, Tianjin
2025-01-01
Recruiting
Kong Fanming
Phase 2/3
405
Tianjin
2025-01-01
Active, closed
Tianjin Medical University
Phase 4
30
Tianjin
2025-01-01
Recruiting
Gang Wang
Not applicable
214
Wuhu, Beijing, Guangzhou, Shijiazhuang, Jining, Chengdu, Tianjin, Dali
2025-01-01
Recruiting
TTE Improves Clinical Management of Stable Chest Pain
NCT07063147Transthorcic Echocardiography, Stable Angina Pectoris, Coronary Artery Disease, Major Adverse Cardiac Events
Tianjin Chest Hospital
Observational
50,000
Tianjin
2025-01-01
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Phase 2
130
Tianjin
2025-01
Not yet open
A Study of 3D Visualization Techniques to Improve the Quality and Safety of Robot-assisted Nephron Sparing Surgery for Complex Renal Tumors.
NCT06717009Kidney Neoplasms / Surgery, Robotic Surgical Procedures, Imaging, Three-Dimensional / Methods, Nephrectomy / Methods
Tianjin Medical University Cancer Institute and Hospital
Not applicable
350
Tianjin
2025-01
Recruiting
BCMA/CD3 BsAb in the Treatment of High-risk Smoldering Multiple Myeloma
NCT06745687High Risk Smoldering Multiple Myeloma
DrugCM336
Institute of Hematology & Blood Diseases Hospital, China
Not applicable
20
Tianjin
2024-12-30
Active, closed
Efficacy and Safety of ZVS101e in Patients With Bietti 's Crystalline Dystrophy
NCT06743646Bietti Crystalline Corneoretinal Dystrophy, Bietti Crystalline Dystrophy
DrugZVS101e
Chigenovo Co., Ltd
Phase 3
63
Beijing, Guangzhou, Zhengzhou, Chengdu, Tianjin
2024-12-27
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Phase 1
21
Tianjin
2024-12-25
Recruiting
JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas
NCT06716658Lymphoma, T-Cell, NK-LGL Leukemia, T-LGL Leukemia, Cutaneous T Cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
48
Tianjin
2024-12-25
By invitation
Tianjin Central Hospital of Gynecology Obstetrics
Observational
600
Tianjin
2024-12-25
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Phase 2
20
Tianjin
2024-12-20
Recruiting
Nanjing IASO Biotechnology Co., Ltd.
Observational
1,500
Beijing, Tianjin, Wuhan, Zhengzhou
2024-12-15
Recruiting
Shanghai Mental Health Center
Not applicable
60
Guangzhou, Shijiazhuang, Xinxiang, Nanchang, Taiyuan, Mianyang, Shanghai, Tianjin
2024-12-14
Recruiting
Phase Ib Trial of HS-20117 in Combination With Other Drugs in Advanced Solid Tumors
NCT06621563Solid Tumors, Non-Small Cell Lung Cancer, Colorectal Cancer
DrugsHS-20117·Capeox·MFOLFOX6·Folfox
Hansoh BioMedical R&D Company
Phase 1
780
Tianjin
2024-12-14
Recruiting
Long-term Follow-up Study of BRL-101 for TDT
NCT06298630Thalassemia, Beta
Bioray Laboratories
Observational
45
Guangzhou, Shenzhen, Nanning, Changsha, Tianjin, Guangxi
2024-12-08
Recruiting
A Multicenter, Prospective, Cohort Study of Trop-2 ADC Combination Therapy for Advanced Triple-negative Breast Cancer
NCT06878625Evaluating the Efficacy of Trop-2 ADC Combination Therapy in Advanced Triple-Negative Breast Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2
138
Tianjin
2024-12-06
Active, closed
CAR T-cell Therapy Targeting CD19 and BCMA in Patients With AIHA Who Have Failed ≥3 Lines of Therapy.
NCT06733610Autoimmune Hemolytic Anemia, CD19/BCMA CAR T-cells, Universal Allogeneic CAR T-cells
Institute of Hematology & Blood Diseases Hospital, China
Phase 1
5
Tianjin
2024-12-05
Recruiting
ALI & Pulmonary HA Deposition After SAH
NCT06628531Subarachnoid Haemorrhage (SAH)
Tianjin Medical University
Observational
24
Tianjin
2024-12-01
Recruiting
Tianjin Huanhu Hospital
Not applicable
64
Tianjin
2024-12-01
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Phase 2
34
Tianjin
2024-12-01
Active, closed
Growth Evaluation, Health Promotion, and Clinical Management in Children and Adolescents With Thalassemia
NCT06931912Thalassemia Intermedia, Thalassemia Major, Growth Delay, Puberty, Delayed
Institute of Hematology & Blood Diseases Hospital, China
Not applicable
385
Tianjin
2024-12-01
Not yet open
Tianjin Medical University Cancer Institute and Hospital
Phase 3
430
Tianjin
2024-12
Recruiting
Wuhan Createrna Science and Technology Co., Ltd
Phase 2/3
120
Tianjin
2024-11-30
Recruiting
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
NCT06526793B-cell Non-Hodgkin Lymphoma, Follicular Lymphoma (FL), Large B-Cell Lymphoma (LBCL)
DrugSurovatamig
AstraZeneca
Phase 2
270
Chengdu, Guangzhou, Nanchang, Nanjing, Nantong, Shandong, Shanghai, Tianjin
2024-11-27
Recruiting
Tianjin Medical University Second Hospital
Phase 1/2
65
Tianjin
2024-11-27
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Phase 2
134
Tianjin
2024-11-19
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Phase 2
30
Tianjin
2024-11-16
Active, closed
Xijing Hospital
Phase 2
116
Shijiazhuang, Xi'an, Tianjin
2024-11-15
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Early Phase 1
15
Tianjin
2024-11-15
Active, closed
Institute of Hematology & Blood Diseases Hospital, China
Observational
500
Tianjin
2024-11-14
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Phase 2
70
Tianjin
2024-11-12
Active, closed
Tianjin Medical University Cancer Institute and Hospital
Phase 2
110
Tianjin
2024-11-12
Active, closed
Keymed Biosciences Co.Ltd
Phase 2
62
Tianjin
2024-11-11
Recruiting
The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors
NCT06911710Lymphoma, B-cell, Aggressive Non-Hodgkin (B-NHL), AML (Acute Myelogenous Leukemia), Myeloma Multiple, B-ALL
Tianjin Medical University General Hospital
Phase 1/2
90
Tianjin
2024-11-09
Recruiting
Safety Study of CC312 in Autoimmune Disease Patients
NCT06888960Systemic Lupus Erythematosus (SLE), Idiopathic Inflammatory Myopathy (IIM), Systemic Sclerosis (SSc), Rheumatoid Arthritis (RA)
DrugCC312
CytoCares Inc
Early Phase 1
18
Tianjin
2024-11-08
Recruiting
89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP Study
NCT06750419Clear Cell Renal Cell Carcinoma
Telix Pharmaceuticals (Innovations) Pty Limited
Phase 3
82
Beijing, Hangzhou, Hubei, Shanghai, Suzhou, Tianjin, Wuxi, Zhejiang
2024-11-06
Recruiting
Tianjin Medical University Second Hospital
Phase 2
300
Tianjin
2024-11-01
Not yet open
Abnormal Glucose Tolerance in Allogeneic Hematopoietic Stem Cell Transplantation
NCT06704542ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION, Diabetes Mellitus, Impaired Fasting Glucose
Ruijin Hospital
Observational
1,000
Zhengzhou, Wuhan, Shanghai, Hangzhou, Tianjin
2024-11
Active, closed
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
48
Tianjin
2024-10-24
Recruiting
Shanghai Zhongshan Hospital
Phase 2
100
Shantou, Shenyang, Shanghai, Tianjin, Hangzhou
2024-10-24
Recruiting
argenx
Phase 3
69
Beijing, Bengbu, Chengde, Hohhot, Huai'an, Huizhou, Tianjin, Wuhan
2024-10-18
Recruiting
Suzhou BlueHorse Therapeutics Co., Ltd.
Early Phase 1
10
Tianjin
2024-10-17
Active, closed
Novartis Pharmaceuticals
Phase 2
203
Nanning, Zhengzhou, Chengdu, Ningbo, Beijing, Tianjin
2024-10-09
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Phase 1/2
66
Tianjin
2024-10-08
Recruiting
Tianjin Eye Hospital
Not applicable
100
Tianjin
2024-10-01
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Phase 2
84
Tianjin
2024-10-01
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
380
Tianjin
2024-09-29
Recruiting
Tianjin Medical University Second Hospital
Phase 1/2
72
Tianjin
2024-09-24
Recruiting
Pierre Fabre Medicament
Phase 1/2
171
Shanghai, Tianjin
2024-09-17
Active, closed
Pierre Fabre Medicament
Observational
368
Tianjin
2024-09-10
Recruiting
Wayshine Biopharm, Inc.
Phase 1/2
100
Hefei, Beijing, Guangzhou, Zhengzhou, Jinan, Shanghai, Chengdu, Tianjin
2024-09-04
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Phase 2
46
Tianjin
2024-09-01
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Phase 2
33
Tianjin
2024-09-01
Recruiting
A Study of the Effect of Real-time Pressure Controllers on Subjective and Objective Symptoms of Peripheral Neuropathy Induced by Albumin Paclitaxel
NCT07019233Real Time Pressure Controller, Breast Cancer, Albumin Paclitaxel, Peripheral Neuropathy
Tianjin Medical University Cancer Institute and Hospital
Not applicable
118
Tianjin
2024-09-01
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Phase 2
40
Tianjin
2024-09-01
Not yet open
A Study of QLS4131 in Patients With Recurrent or Refractory Multiple Myeloma
NCT06500507Relapsed or Refractory Multiple Myeloma
DrugQLS4131
Qilu Pharmaceutical Co., Ltd.
Phase 1
90
Tianjin
2024-08-30
Recruiting
Wuhan Createrna Science and Technology Co., Ltd
Phase 3
66
Beijing, Tianjin
2024-08-30
Active, closed
Amgen
Phase 2
32
Beijing, Chongqing, Fuzhou, Guangzhou, Jiangmen, Harbin, Wuhan, Tianjin
2024-08-27
Active, closed
Zenas BioPharma (USA), LLC
Phase 2
93
Beijing, Suzhou, Tianjin, Ürümqi, Wuhan
2024-08-26
Recruiting
CD19-targeted CAR T Cells for Relapsed or Refractory (R/R) Large B-cell Lymphoma
NCT06479356Non-Hodgkin Lymphoma, Large B-cell Lymphoma
DrugRelma-cel
Shanghai Ming Ju Biotechnology Co., Ltd.
Phase 2
12
Tianjin
2024-08-15
Active, closed
Novartis Pharmaceuticals
Phase 1/2
20
Tianjin
2024-08-14
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Not applicable
148
Tianjin
2024-08-13
Recruiting
Thalidomide for the Symptomatic Large Granular Lymphocytic Leukemia
NCT06530576T-LGL Leukemia, NK-LGL Leukemia
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
48
Tianjin
2024-08-10
Recruiting
PI3K Inhibitors for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas
NCT06530550Lymphoma, T-Cell, NK-LGL Leukemia, T-LGL Leukemia
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
51
Tianjin
2024-08-10
Recruiting
IASO-782 in Autoimmune Hematological Diseases
NCT06534021Autoimmune Thrombocytopenia, Warm Autoimmune Haemolytic Anaemia
DrugIASO-782
Shanghai IASO Biotechnology Co., Ltd
Phase 1
16
Wuhan, Tianjin
2024-08-08
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Not applicable
184
Tianjin
2024-08-05
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
30
Tianjin
2024-08-01
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Phase 2
36
Tianjin
2024-08-01
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Phase 2
30
Tianjin
2024-08-01
Recruiting
Tianjin Anding Hospital
Not applicable
100
Tianjin
2024-08-01
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
20
Tianjin
2024-08-01
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Phase 2
200
Tianjin
2024-07-25
Active, closed
Study of Blinatumomab Administration in Chinese Pediatric Participants With Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
NCT06054113B Precursor Acute Lymphoblastic Leukemia, Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia
DrugBlinatumomab
Amgen
Phase 2
18
Hefei, Chongqing, Guangzhou, Wuhan, Suzhou, Shanghai, Tianjin
2024-07-23
Recruiting
GlaxoSmithKline
Phase 3
150
Guangzhou, Shanghai, Tianjin
2024-07-19
Active, closed
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
39
Tianjin
2024-07-18
Active, closed
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
74
Tianjin
2024-07-11
Recruiting
Colorado Prevention Center
Phase 3
1,500
Guangzhou, Changsha, Jinan, Shanghai, Taiyuan, Xian City, Chengdu, Tianjin
2024-07-09
Recruiting
Lingyi Biotech Co., Ltd.
Phase 1/2
12
Guangzhou, Taiyuan, Tianjin
2024-07-05
Recruiting
The Effect of Serum Ferritin in irAE
NCT06702566Immune-related Adverse Event, Malignant Solid Tumors, Acute Leukemia, Serum Ferritin
Tianjin Medical University Cancer Institute and Hospital
Not applicable
1,500
Tianjin
2024-07-04
Active, closed
Novartis Pharmaceuticals
Phase 4
36
Guangzhou, Zhengzhou, Wuhan, Xian, Hangzhou, Beijing, Taian, Tianjin
2024-07-04
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Phase 2
64
Tianjin
2024-07-01
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Phase 2
25
Tianjin
2024-07-01
Not yet open
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2
54
Beijing, Zhengzhou, Changsha, Changchun, Jinan, Shanghai, Taiyuan, Tianjin
2024-07
Recruiting
Chengdu Origen Biotechnology Co., Ltd.
Phase 1/2
44
Tianjin
2024-06-28
Recruiting
Boehringer Ingelheim
Phase 1/2
910
Changchun, Hangzhou, Harbin, Nanjing, Shanghai, Tianjin, Zhengzhou
2024-06-28
Recruiting
Tianjin Huanhu Hospital
Not applicable
350
Tianjin
2024-06-25
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
20
Tianjin
2024-06-25
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Phase 2
60
Tianjin
2024-06-19
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Phase 1/2
20
Tianjin
2024-06-15
Recruiting
RemeGen Co., Ltd.
Phase 1/2
24
Guangzhou, Wuhan, Changsha, Nanjing, Chengdu, Tianjin
2024-06-14
Recruiting
Ascentage Pharma Group Inc.
Phase 3
486
Tianjin, Hangzhou
2024-06-11
Recruiting
Efficacy and Safety of Chemotherapy Combined With CAR-T Cells in Newly Diagnosed Adult Patients With Ph- B-ALL
NCT06481241Philadelphia Chromosome Negative ALL, Acute Lymphoblastic Leukemia, Adult
DrugVenetoclax
Institute of Hematology & Blood Diseases Hospital, China
Not applicable
77
Tianjin
2024-06-10
Recruiting
Shandong Suncadia Medicine Co., Ltd.
Phase 1
233
Tianjin
2024-06-06
Recruiting
Efficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALL
NCT06481228Philadelphia Positive Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, Adult
DrugsOlverembatinib·Venetoclax
Institute of Hematology & Blood Diseases Hospital, China
Not applicable
82
Tianjin
2024-06-04
Not yet open
Tianjin Medical University Cancer Institute and Hospital
Phase 2
158
Tianjin
2024-06
Recruiting
Shanghai RAAS Blood Products Co., Ltd.
Phase 1/2
76
Changsha, Hefei, Jinan, Lanzhou, Shanghai, Taiyuan, Tianjin, Xi'an
2024-05-31
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Phase 1/2
108
Tianjin
2024-05-30
Active, closed
A Study of JNJ-88998377 for Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
NCT06470438Lymphoma, Non-Hodgkin, Refractory B-Cell NHL, Relapsed B-cell NHL
Janssen Research & Development, LLC
Phase 1
58
Beijing, Guangzhou, Hangzhou, Shanghai, Tianjin
2024-05-28
Recruiting
Hansoh BioMedical R&D Company
Phase 2/3
1,080
Tianjin, Hangzhou
2024-05-28
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
89
Tianjin
2024-05-28
Active, closed
Institute of Hematology & Blood Diseases Hospital, China
Phase 1/2
53
Tianjin
2024-05-27
Recruiting
Linperlisib Combined With Chidamide in Patients With PTCL
NCT06421948Peripheral T-cell Lymphoma
Yanyan Liu
Phase 1/2
134
Zhengzhou, Wuhan, Changsha, Chengdu, Tianjin, Hangzhou
2024-05-25
Recruiting
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 1
130
Beijing, Fuzhou, Guangzhou, Zhengzhou, Nanjing, Tianjin, Hanzhou
2024-05-24
Recruiting
A Study of GQ1010 in Subjects With Advanced Solid Tumors
NCT06464055Advanced Malignant Solid Tumors
DrugPhase II
GeneQuantum Healthcare (Suzhou) Co., Ltd.
Phase 1/2
260
Beijing, Harbin, Tianjin, Wuhan, Zhengzhou
2024-05-23
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Observational
50
Tianjin
2024-05-15
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Not applicable
537
Tianjin
2024-05-11
Recruiting
Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
NCT06395870B-Cell Non-Hodgkin Lymphoma-Recurrent, B-Cell Non-Hodgkin Lymphoma-Refractory
Tianjin Medical University Cancer Institute and Hospital
Phase 1
33
Hefei, Tianjin
2024-05-09
Active, closed
Chengdu Zenitar Biomedical Technology Co., Ltd
Phase 2
75
Chengdu, Tianjin
2024-05-06
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Not applicable
24
Tianjin
2024-05-06
Not yet open
Tianjin Medical University Cancer Institute and Hospital
Phase 2/3
146
Tianjin
2024-05-01
Not yet open
Tianjin Eye Hospital
Not applicable
138
Tianjin
2024-05
Not yet open
Akeso
Phase 1/2
180
Tianjin
2024-04-29
Recruiting
Study Evaluating ISM8207 in Participants With Advanced Solid Tumors and Relapsed/Refractory B-Cell Lymphoma
NCT06445517Advanced Solid Tumors, Relapsed/Refractory B-cell Lymphoma
InSilico Medicine Hong Kong Limited
Phase 1
60
Beijing, Nanchang, Shanghai, Tianjin
2024-04-25
Recruiting
yilong Wang
Not applicable
134
Wuhu, Beijing, Tangshan, Xi'an, Tianjin
2024-04-22
Recruiting
A Clinical Study of CHT101 in CD70-Positive Advanced Solid Tumors
NCT06730659Relapsed / Refractory Solid Tumor
DrugCHT101
Tianjin Medical University Cancer Institute and Hospital
Phase 1
36
Tianjin
2024-04-19
Recruiting
Kong Fanming
Not applicable
84
Tianjin
2024-04-17
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
30
Tianjin
2024-04-12
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Phase 2
32
Tianjin
2024-04-09
Active, closed
Janssen Research & Development, LLC
Phase 3
272
Beijing, Cheng Du Shi, Chongqing, Guangzhou, Shenyang, Tianjin, Wenzhou, Wuhan
2024-04-09
Recruiting
Ting Deng
Phase 1
9
Tianjin
2024-04-08
Recruiting
Ascentage Pharma Group Inc.
Phase 3
344
Bengbu, Guangzhou, Zhanjiang, Zhengzhou, Wuhan, Changsha, Shanghai, Tianjin
2024-04-07
Recruiting
β-Thalassemia Treatment With KL003 Cell Injection
NCT06280378Transfusion-dependent Beta-Thalassemia
Kanglin Biotechnology (Hangzhou) Co., Ltd.
Phase 1/2
41
Shanghai, Tianjin
2024-04-05
Recruiting
Tianjin Eye Hospital
Not applicable
40
Tianjin
2024-04-02
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
53
Tianjin
2024-04-02
Recruiting
Tianjin Medical University General Hospital
Phase 2
50
Tianjin
2024-04-01
Recruiting
Tianjin Medical University Second Hospital
Observational
110
Tianjin
2024-04-01
Active, closed
Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B Without Inhibitors
NCT06569108Hemophilia A Without Inhibitor, Hemophilia B Without Inhibitor
DrugKN057
Suzhou Alphamab Co., Ltd.
Phase 3
125
Tianjin
2024-04-01
Not yet open
Sinocelltech Ltd.
Phase 1
76
Beijing, Zhengzhou, Tianjin
2024-04
Recruiting
Juventas Cell Therapy Ltd.
Observational
1,000
Tianjin
2024-03-30
Recruiting
Medtecx Co Ltd.
Not applicable
126
Hefei, Beijing, Wuhan, Nanjing, Nanchang, Xi'an, Shanghai, Tianjin
2024-03-26
Recruiting
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 1
108
Zhengzhou, Wuhan, Nanchang, Tianjin, Hangzhou
2024-03-21
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Phase 2
20
Tianjin
2024-03-20
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Phase 2
51
Tianjin
2024-03-20
Recruiting
TGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies
NCT06206174Hematologic Malignancy, Non Hodgkin Lymphoma, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Adult
Shenzhen TargetRx Co., Ltd.
Phase 1/2
30
Tianjin
2024-03-06
Recruiting
Multicenter Prospective Cohort Study of Twin Maternal-Child Dyads in China
NCT06414655Twin Pregnancy, Antepartum Condition or Complication, Twin to Twin Transfusion as Antepartum Condition, Pre-Term, Pre-Eclampsia
Peking University Third Hospital
Observational
2,000
Hefei, Beijing, Chongqing, Guangzhou, Shenyang, Jinan, Shanghai, Tianjin
2024-03-01
Recruiting
Avatrombopag in the Treatment of Pediatric Immune Thrombocytopenia
NCT06281327Immune Thrombocytopenia, Treatment
DrugAvatrombopag
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
60
Tianjin
2024-03-01
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Not applicable
456
Tianjin
2024-02-29
Active, closed
Tianjin Medical University General Hospital
Phase 1/2
100
Tianjin
2024-02-29
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Not applicable
458
Tianjin
2024-02-22
By invitation
Tianjin Anding Hospital
Observational
200
Tianjin
2024-02-19
Recruiting
Akeso
Phase 2
90
Tianjin
2024-02-07
Active, closed
Chengdu Suncadia Medicine Co., Ltd.
Phase 2
132
Beijing, Tianjin
2024-02-06
Active, closed
CNCT19 for Patients With Autoimmune Hemolytic Anemia After Failure ≥3 Lines of Therapy.
NCT06231368Autoimmune Hemolytic Anemia, Autologous CD19 CAR-T, Failure of Three or More Lines of Therapy
Institute of Hematology & Blood Diseases Hospital, China
Phase 1
6
Tianjin
2024-02-04
Recruiting
Study SC-101 in Subjects With Advanced Malignancies
NCT06220838Advanced Solid Tumor
Tianjin ConjuStar Biologics Co., Ltd.
Phase 1
100
Beijing, Changsha, Nanjing, Shanghai, Tianjin
2024-02-02
Recruiting
Ruihua Wei
Phase 1/2
410
Tianjin
2024-02-01
Recruiting
Zhu Xiaofan
Not applicable
60
Tianjin
2024-02-01
Active, closed
Innostellar Biotherapeutics Co.,Ltd
Phase 2
50
Hefei, Hangzhou, Beijing, Chengdu, Guangzhou, Shanghai, Taiyuan, Tianjin
2024-01-24
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Not applicable
35
Tianjin
2024-01-20
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Early Phase 1
6
Tianjin
2024-01-17
Recruiting
GVM±R in Patients With Relapsed or Refractory Aggressive NHL.
NCT06244368Peripheral T Cell Lymphoma, Diffuse Large B-cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
115
Tianjin
2024-01-17
Recruiting
Tianjin Medical University General Hospital
Phase 2
25
Tianjin
2024-01-17
Active, closed
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
45
Tianjin
2024-01-16
Active, closed
Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B With Inhibitors
NCT06312475Hemophilia A With Inhibitor, Hemophilia B With Inhibitor
DrugKN057
Suzhou Alphamab Co., Ltd.
Phase 3
53
Tianjin
2024-01-09
Recruiting
Chengdu New Radiomedicine Technology Co. LTD.
Phase 1
58
Zhengzhou, Suzhou, Shanghai, Chongqing, Tianjin
2024-01-09
Recruiting
CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALL
NCT06179524Relapsed B-cell Acute Lymphoblastic Leukemia, Refractory B-cell Acute Lymphoblastic Leukemia
DrugCar-T
Beijing Yongtai Ruike Biotechnology Company Ltd
Phase 2
100
Tianjin
2024-01-03
Recruiting
Shanghai Lanyi Therapeutics Co., Ltd.
Phase 1
24
Tianjin, Hangzhou
2024-01-03
Active, closed
Institute of Hematology & Blood Diseases Hospital, China
Phase 1
30
Tianjin
2024-01-01
Recruiting
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
NCT06137118B-cell Acute Lymphoblastic Leukemia (B-ALL)
DrugSurovatamig
AstraZeneca
Phase 1/2
255
Changsha, Chengdu, Guangzhou, Hangzhou, Nanjing, Suzhou, Tianjin, Zhengzhou
2023-12-29
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
60
Tianjin
2023-12-28
Recruiting
RenJi Hospital
Not applicable
1,200
Nanjing, Nanchang, Jinan, Shanghai, Xi’an, Tianjin, Hangzhou
2023-12-27
Active, closed
nthalmic Pty Ltd
Not applicable
210
Tianjin, Shanghai
2023-12-22
Recruiting
Janssen Research & Development, LLC
Phase 1
300
Beijing, Hangzhou, Tianjin
2023-12-20
Recruiting
Li Xiaorong
Early Phase 1
6
Tianjin
2023-12-20
Active, closed
AbbVie
Phase 3
614
Beijing, Guangzhou, Wuhan, Xi'an, Jinan, Shanghai, Chengdu, Tianjin
2023-12-19
Recruiting
Shanghai Refreshgene Technology Co., Ltd.
Phase 1/2
48
Tianjin
2023-12-12
Recruiting
Tianjin Chest Hospital
Not applicable
800
Beijing, Lanfang, Tianjin
2023-12-11
Not yet open
Efficacy and Safety of Immunosuppressive Withdrawal After Pediatric Liver Transplantation
NCT06147375Immune Tolerance, Immunosuppression, Liver Transplant; Complications
DrugsCyclosporine A·Tacrolimus
Wei Gao
Not applicable
47
Tianjin
2023-12-01
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
60
Tianjin
2023-12-01
Not yet open
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 1/2
129
Jinan, Tianjin
2023-12
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
40
Tianjin
2023-12
Recruiting
Cohort of Nursing Homes
NCT07249086Health Status
Institute of Hematology & Blood Diseases Hospital, China
Observational
1,500
Tianjin
2023-11-30
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Phase 4
50
Tianjin
2023-11-22
Active, closed
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
1,615
Shanghai, Tianjin
2023-11-20
Recruiting
3D Medicines (Sichuan) Co., Ltd.
Phase 3
390
Tianjin
2023-11-17
Recruiting
Identification of Plasma Biomarkers for Early Diagnosis of Transplant-associated Thrombotic Microangiopathy
NCT06102694Thrombotic Microangiopathies, Hematopoietic Stem Cell Transplantation
Institute of Hematology & Blood Diseases Hospital, China
Observational
500
Tianjin
2023-11-16
Recruiting
RenJi Hospital
Phase 2
22
Nanjing, Xi'an, Shanghai, Chengdu, Tianjin
2023-11-16
Recruiting
Gene Therapy for DME
NCT06492876Diabetic Macular Edema
Frontera Therapeutics
Phase 1/2
78
Tianjin
2023-11-15
Recruiting
Akeso
Phase 2
90
Tianjin
2023-11-13
Recruiting
Takeda
Phase 3
80
Beijing, Guangzhou, Shenzhen, Shanghai, Tianjin
2023-11-13
Active, closed
AstraZeneca
Phase 3
314
Beijing, Guangzhou, Hangzhou, Lanzhou, Shanghai, Tianjin
2023-11-08
Active, closed
Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL
NCT06093841Lymphoma, Large B-Cell, Diffuse, Follicular Lymphoma Grade 3B, High-grade B-cell Lymphoma, Mediastinal B-Cell Diffuse Large Cell Lymphoma
DrugsRelmacabtagene Autoleucel·Relma-cel·Fludarabine·Cyclophosphamide
Shanghai Ming Ju Biotechnology Co., Ltd.
Phase 2
46
Guangzhou, Zhengzhou, Changsha, Suzhou, Jinan, Shanghai, Tianjin, Hangzhou
2023-11-03
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Observational
500
Tianjin
2023-11-01
Recruiting
Pan-Amyloid PET/CT in Various Amyloid-Related Disease
NCT07130565Amyloid, Cardiac Amyloidosis, Amyloidosis
Tianjin Medical University
Observational
500
Hefei, Qingdao, Tianjin
2023-11-01
Recruiting
Tianjin Huanhu Hospital
Observational
200
Tianjin
2023-11-01
Recruiting
IN10018 Combination Therapy in Treatment-naïve ES-SCLC
NCT06030258Small Cell Lung Cancer Extensive Stage
DrugsIN10018·Etoposide·Tislelizumab·Carboplatin
InxMed (Shanghai) Co., Ltd.
Phase 1/2
120
Jinan, Tianjin, Zhengzhou
2023-10-30
Active, closed
Institute of Hematology & Blood Diseases Hospital, China
Not applicable
113
Tianjin
2023-10-01
By invitation
Berberine in Treating Negative Symptoms of Schizophrenia: Clinical Efficacy and Mechanisms
NCT07356765Schizophrenia, Negative Symptoms of Schizophrenia
DrugBerberine
Tianjin Anding Hospital
Not applicable
120
Tianjin
2023-09-26
Active, closed
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
165
Beijing, Lanzhou, Tangshan, Shanghai, Tianjin
2023-09-21
Active, closed
Efficacy and Safety of LX101 for Inherited Retinal Dystrophy Associated With RPE65 Mutations
NCT07054632Inherited Retinal Dystrophy Associated With RPE65 Mutations
Innostellar Biotherapeutics Co.,Ltd
Phase 3
30
Guangzhou, Chongqing, Shanghai, Tianjin
2023-09-13
Recruiting
Tasly Pharmaceutical Group Co., Ltd
Phase 3
408
Beijing, Lanzhou, Shijiazhuang, Luoyang, Wuhan, Suzhou, Nanchong, Tianjin
2023-09-11
Recruiting
Phase I Clinical Trial of RC19D2 Cell Injection in the Treatment of Diffuse Large B-cell Lymphoma
NCT06047197Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma
Beijing Yongtai Ruike Biotechnology Company Ltd
Phase 1
25
Tianjin
2023-09-05
Active, closed
HELP Therapeutics Co., Ltd.
Phase 1/2
36
Tianjin
2023-09-05
Recruiting
HuidaGene Therapeutics Co., Ltd.
Early Phase 1
12
Shanghai, Tianjin
2023-09-04
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Phase 2
268
Tianjin
2023-09-01
Active, closed
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1/2
3
Tianjin
2023-08-16
Recruiting
Gene Therapy(FT-003) for Wet AMD
NCT06492863Neovascular Age-related Macular Degeneration
Frontera Therapeutics
Phase 1/2
78
Tianjin
2023-08-15
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
20
Tianjin
2023-08-14
Recruiting
Safety Study of CC312 in Adult Patients With Relapsed/Refractory CD19 Positive B-cell Hematologic Malignancies
NCT06037018Non-hodgkin Lymphoma, Acute Lymphoblastic Leukaemia, Chronic Lymphocytic Leukemia
DrugCC312
CytoCares Inc
Phase 1
44
Tianjin
2023-08-07
Active, closed
nthalmic Pty Ltd
Not applicable
441
Wenzhou, Tianjin, Shanghai
2023-08-04
By invitation
Personalized SBRT in Early-Stage Peripheral NSCLC
NCT07167459Early-stage Peripheral Non-small Cell Lung Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2
251
Tianjin
2023-08-04
Recruiting
A Study of BL-M11D1 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
NCT05924750Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
DrugBL-M11D1
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
130
Hefei, Beijing, Haerbin, Shenyang, Jinan, Shanghai, Chengdu, Tianjin
2023-08-02
By invitation
Posaconazole Tablet As Primary Prophylaxis of HSCT Patients with Gastrointestinal GVHD
NCT06698211Invasive Fungal Disease, Graft Versus Host Disease, Hematopoietic Stem Cell Transplantation
DrugPosaconazole
Institute of Hematology & Blood Diseases Hospital, China
Observational
40
Tianjin
2023-08-01
Recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Observational
380
Beijing, Tianjin
2023-08
Active, closed
HOYA Lens Thailand LTD.
Not applicable
249
Beijing, Guangzhou, Shanghai, Shengyang, Tianjin
2023-07-31
Recruiting
RemeGen Co., Ltd.
Phase 2
120
Changsha, Shanghai, Tianjin, Hangzhou
2023-07-27
Recruiting
Lin BioScience, Inc
Phase 1/2
90
Xinxiang, Jining, Tianjin
2023-07-20
Not yet open
Hansoh BioMedical R&D Company
Phase 1
322
Tianjin
2023-07-20
Active, closed
Gritgen Therapeutics Co., Ltd.
Phase 1/2
7
Wuhan, Tianjin
2023-07-10
Recruiting
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
220
Shanghai, Tianjin
2023-07-06
Active, closed
CS1-Targeted CAR-T Cells for Relapsed/Refractory Multiple Myeloma
NCT07809594Relapsed/Refractory Multiple Myeloma (RRMM), Plasma Cell Myeloma
Institute of Hematology & Blood Diseases Hospital, China
Phase 1
10
Tianjin
2023-07-05
Active, closed
Tianjin Medical University Cancer Institute and Hospital
Phase 1/2
106
Tianjin
2023-07-01
Recruiting
Pre-pectoral Breast Reconstruction With or Without Mesh
NCT05888571Prepectoral Breast Reconstruction, TiLOOP Mesh
Tianjin Medical University Cancer Institute and Hospital
Not applicable
164
Tianjin
2023-07-01
Recruiting
Tianjin Medical University
Early Phase 1
15
Tianjin
2023-07-01
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
94
Tianjin
2023-06-30
Recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 4
360
Hefei, Beijing, Lanzhou, Nanning, Shijiazhuang, Tianjin, Zhengzhou, Wuhan
2023-06-19
Recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2
58
Beijing, Fuzhou, Weifang, Shanghai, Taiyuan, Tianjin
2023-06-14
Recruiting
Hansoh BioMedical R&D Company
Phase 2
170
Beijing, Changsha, Guangzhou, Hangzhou, Nanjing, Shanghai, Tianjin, Zhengzhou
2023-06-08
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Observational
100
Tianjin
2023-06-05
Active, closed
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
25
Tianjin
2023-05-23
Active, closed
Institute of Hematology & Blood Diseases Hospital, China
Not applicable
3
Tianjin
2023-05-23
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Phase 4
25
Tianjin
2023-05-22
Recruiting
Gene Therapy for Diabetic Macular Edema
NCT05916391Diabetic Macular Edema
Frontera Therapeutics
Phase 1
18
Tianjin
2023-05-19
Not yet open
Real World Study of Linperlisib for Lymphoma Treatment
NCT05863871Focus on the Lymphoma Including B/T-cell Lymphoma
DrugLinperlisib
Ruijin Hospital
Observational
1,000
Shanghai, Tianjin
2023-05
Recruiting
Bioray Laboratories
Phase 1
18
Wuhan, Tianjin, Hangzhou
2023-04-25
Active, closed
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
20
Tianjin
2023-04-21
Recruiting
ZHOU FANGJIAN
Phase 3
298
Beijing, Guangzhou, Hefei, Shanghai, Sichuan, Tianjin, Zhengzhou
2023-04-19
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Not applicable
6
Tianjin
2023-04-19
Recruiting
Comparison of the Outcomes of Single vs Multiple Arterial Grafts in Women
NCT04124120Heart Diseases, Coronary Artery Disease, Coronary Artery Bypass Grafting
Weill Medical College of Cornell University
Not applicable
2,300
Beijing, Changchun, Shanghai, Tianjin
2023-04-17
Active, closed
Tianjin Medical University General Hospital
Phase 1
11
Tianjin
2023-04-15
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Phase 2
148
Huizhou, Nanyang, Lianyungang, Weihai, Tianjin
2023-04-12
Active, closed
Tianjin Medical University Cancer Institute and Hospital
Phase 2
30
Tianjin
2023-04-12
By invitation
Sanofi
Phase 2
70
Tianjin
2023-04-05
Active, closed
Sanofi
Phase 2
118
Changsha, Guangzhou, Nanchang, Shenyang, Tianjin, Wuhan
2023-04-05
Active, closed
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
40
Tianjin
2023-04-04
Active, closed
Bayer
Phase 3
985
Beijing, Wuhan, Changsha, Nanjing, Shanghai, Chengdu, Tianjin, Hangzhou
2023-04-03
Not yet open
A Study of KM501 in Patients With Solid Tumors
NCT05804864Advanced Solid Tumors
Xuanzhu Biopharmaceutical Co., Ltd.
Phase 1
96
Tianjin
2023-04
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Phase 1
9
Tianjin
2023-03-23
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
37
Tianjin
2023-03-02
Active, closed
Tianjin Medical University Eye Hospital
Observational
100
Tianjin
2023-03-01
Recruiting
Ascentage Pharma Group Inc.
Phase 1/2
100
Guangzhou, Wuhan, Tianjin
2023-02-28
Active, closed
Novartis Pharmaceuticals
Phase 2
33
Changchun, Tianjin
2023-02-28
Recruiting
Rituximab for Serious Aplastic Anemia With Platelet Transfusion Refractoriness
NCT06254560Severe Aplastic Anemia, Platelet Transfusion Refractoriness
DrugRituximab
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
20
Tianjin
2023-02-23
Recruiting
Xijing Hospital of Digestive Diseases
Phase 3
150
Lanzhou, Guangzhou, Nanjing, Shenyang, Xi'an, Chengdu, Tianjin
2023-02-22
Active, closed
Chigenovo Co., Ltd
Phase 1/2
24
Beijing, Chengdu, Tianjin
2023-02-20
Active, closed
A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A
NCT05685238Haemophilia A, Haemophilia A With Inhibitors
Novo Nordisk A/S
Phase 3
451
Beijing, Guangzhou, Wuhan, Changsha, Jinan, Chengdu, Tianjin, Huzhou
2023-02-13
Recruiting
Juventas Cell Therapy Ltd.
Phase 1/2
47
Hefei, Chongqing, Guangzhou, Wuhan, Nanjing, Xuzhou, Nanchang, Tianjin
2023-02-07
By invitation
Tianjin Anding Hospital
Observational
230
Tianjin
2023-02-07
Active, closed
Assessment of DOT Spectacles in Chinese Children
NCT05562622Juvenile Myopia, Myopia
SightGlass Vision, Inc.
Not applicable
195
Changsha, Chengdu, Guangzhou, Shanghai, Tianjin
2023-02-05
Active, closed
Novartis Pharmaceuticals
Phase 3
152
Guangzhou, Wuhan, Binzhou, Hangzhou, Beijing, Jinan, Tianjin
2023-02-02
Recruiting
Eli Lilly and Company
Phase 1
677
Beijing, Guangdong, Hangzhou, Shanghai, Tianjin, Xi'an
2023-01-12
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Phase 2
40
Tianjin
2023-01-12
By invitation
Tianjin Medical University Cancer Institute and Hospital
Phase 3
200
Tianjin
2023-01-01
Recruiting
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Phase 1
24
Jinan, Tianjin
2022-12-30
Active, closed
Novartis Pharmaceuticals
Phase 3
90
Guangzhou, Hangzhou, Dalian, Tianjin
2022-12-30
Recruiting
Tianjin Medical University Second Hospital
Phase 2
21
Tianjin
2022-12-30
Active, closed
Tianjin Medical University Cancer Institute and Hospital
Not applicable
60
Tianjin
2022-12-20
Recruiting
Pfizer
Phase 3
100
Beijing, Guangzhou, Guiyang, Wuhan, Nanchang, Tianjin
2022-12-09
Recruiting
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
NCT05579366High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer
DrugsErythromycin·Rina-S·Itraconazole·Bevacizumab
Genmab
Phase 1/2
952
Beijing, Fujian, Guangdong, Henan, Hubei, Shanxi, Shengyang, Tianjin
2022-12-07
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Phase 2
100
Tianjin
2022-12-02
Active, closed
A Study Evaluating Cadonilimab Injection in Combination With Regorafenib for the Advanced Hepatocellular Carcinoma
NCT05644379Advanced Hepatocellular Carcinoma That Has Failed at Least One Prior Systemic Therapy
DrugsRegorafenib·Cadonilimab
Tianjin Medical University Cancer Institute and Hospital
Phase 1
30
Tianjin
2022-11-24
Recruiting
Tianjin Anding Hospital
Observational
300
Tianjin
2022-11-11
Recruiting
Shanghai AbelZeta Ltd.
Phase 1/2
92
Tianjin
2022-11-11
Active, closed
AstraZeneca
Phase 3
368
Beijing, Guangzhou, Hangzhou, Nanjing, Shanghai, Shenyang, Tianjin, Wuhan
2022-11-10
Active, closed
Bioray Laboratories
Phase 1/2
39
Guangzhou, Guanzhou, Shenzhen, Nanning, Changsha, Tianjin
2022-11-02
Active, closed
Safety and Efficacy of Daratumumab in Patients With Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorders
NCT05403138Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder, NMO Spectrum Disorder
DrugsDarzalex·Daratumumab
Tianjin Medical University General Hospital
Phase 2/3
135
Tianjin
2022-11-01
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
59
Tianjin
2022-11-01
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Observational
50
Tianjin
2022-11-01
Active, closed
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
31
Tianjin
2022-10-18
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Phase 2
65
Tianjin
2022-10-14
Active, closed
Tianjin Medical University Second Hospital
Phase 2
100
Tianjin
2022-10-10
Active, closed
Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies
NCT05397496B-cell Non-Hodgkin Lymphoma (B-NHL), B-cell Acute Lymphoblastic Leukemia (B-ALL)
DrugPIT565
Novartis Pharmaceuticals
Phase 1
61
Beijing, Shanghai, Tianjin
2022-10-03
Active, closed
European Myeloma Network B.V.
Phase 3
1,594
Beijing, Changchun, Henan, Shandong, Shanghai, Shenyang, Tangshan, Tianjin
2022-09-08
Active, closed
Toripalimab-based Neoadjuvant Therapy in LA-HNSCC
NCT05522985Head and Neck Squamous Cell Carcinoma, Neoadjuvant Chemotherapy
Tianjin Medical University Cancer Institute and Hospital
Phase 2
122
Tianjin
2022-09-02
Recruiting
Study for Safety and Efficacy of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Ph + ALL
NCT05495035Lymphoblastic Leukemia, Acute, Childhood, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive, Relapsed Leukemia, Refractory Leukemia
Institute of Hematology & Blood Diseases Hospital, China
Phase 1
19
Hefei, Jinan, Tianjin, Shanghai
2022-09-01
Recruiting
Zhejiang Provincial People's Hospital
Phase 2
80
Qingdao, Hangzhou, Ningbo, Tianjin, Wenzhou
2022-09-01
Recruiting
Betta Pharmaceuticals Co., Ltd.
Phase 1
110
Chaoyang, Cangzhou, Tianjin
2022-08-29
Active, closed
Janssen Research & Development, LLC
Phase 1
167
Chongqing, Guangzhou, Tianjin, Wuhan
2022-08-18
Recruiting
Zhuhai Beihai Biotech Co., Ltd
Phase 1/2
48
Beijing, Xiamen, Changsha, Shenyang, Shanghai, Tianjin
2022-08-03
Recruiting
Tianjin Medical University General Hospital
Not applicable
2,000
Tianjin
2022-08-01
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
100
Tianjin
2022-08-01
Recruiting
Tang-Du Hospital
Phase 2
64
Beijing, Changsha, Xi'an, Shanghai, Chengdu, Tianjin
2022-07-21
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Early Phase 1
8
Tianjin
2022-07-19
Recruiting
Fudan University
Observational
385
Hefei, Shijiazhuang, Zhengzhou, Nantong, Taishing, Taizhou, Xi'an, Tianjin
2022-07-18
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Phase 1/2
20
Tianjin
2022-07-14
Active, closed
Biotheus Inc.
Phase 1/2
42
Chongqing, Harbin, Nanjing, Nanchang, Jinan, Shanghai, Yibin, Tianjin
2022-07-01
Active, closed
Safety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002)
NCT05382364Metastatic HER2+ Advanced Breast Cancer, Breast Neoplasms, Gastric or Gastroesophageal Junction Adenocarcinoma (GEC), Colorectal Cancer
DrugTucatinib
Pfizer
Phase 1
25
Harbin, Changsha, Changchun, Shanghai, Tianjin
2022-06-29
Active, closed
Merck Sharp & Dohme LLC
Phase 1
12
Guangzhou, Zhengzhou, Changsha, Tianjin
2022-06-09
Recruiting
Suzhou BlueHorse Therapeutics Co., Ltd.
Phase 1
15
Tianjin
2022-05-30
Active, closed
Grit Biotechnology
Phase 1
31
Beijing, Chongqing, Shanghai, Chengdu, Tianjin
2022-05-23
Active, closed
Institute of Hematology & Blood Diseases Hospital, China
Phase 2/3
312
Tianjin
2022-05-19
Active, closed
Institute of Hematology & Blood Diseases Hospital, China
Phase 1
18
Tianjin
2022-05-15
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Not applicable
1,362
Tianjin
2022-05-01
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
120
Hefei, Beijing, Zhengzhou, Jinan, Tianjin
2022-04-26
Active, closed
Hoffmann-La Roche
Phase 3
208
Chengdu, Fuzhou, Guangzhou, Tianjin, Wuhan, Zhengzhou
2022-04-25
Recruiting
Shanghai Pharmaceuticals Holding Co., Ltd
Early Phase 1
45
Beijing, Taiyuan, Xi’an, Tianjin
2022-04-07
Active, closed
Merck Sharp & Dohme LLC
Phase 3
100
Beijing, Tianjin, Chongqing, Fuzhou, Guangzhou, Shantou, Nanning, Harbin
2022-04-02
Recruiting
National Registry and Cohort Study of Pulmonary Vascular Disease
NCT05368467Pulmonary Arterial Hypertension
Nanjing First Hospital, Nanjing Medical University
Observational
1,000
Guangzhou, Nanjing, Tianjin, Beijing, Changsha, Chendu, Shenyang, Wuhan
2022-03-29
Active, closed
Pfizer
Phase 3
854
Guangzhou, Tianjin, Wenzhou
2022-03-25
Recruiting
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 1
246
Tianjin
2022-03-16
Recruiting
Herombopag for Chemotherapy-induced Thrombocytopenia
NCT05236582Chemotherapy-induced Thrombocytopenia, Herombopag
DrugHerombopag
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
50
Tianjin
2022-03-14
Active, closed
Pfizer
Phase 1/2
235
Changchun, Shanghai, Chengdu, Tianjin, Hangzhou
2022-03-14
Recruiting
Hoffmann-La Roche
Phase 1
332
Beijing, Guangzhou, Nanchang, Tianjin
2022-03-07
Recruiting
FAPI PET/CT in Various FAP-Related Disease Patients
NCT06688071FAP-related Disease, Tumor, Positron Emission Tomography, Metastasis
Tianjin Medical University
Observational
500
Hefei, Qingdao, Tianjin
2022-03-01
Recruiting
Chemokine Receptor 4 PET/CT Imaging of CXCR4-Related Diseases
NCT06690736CXCR4-related Disease, Tumor, Positron Emission Tomography, Metastasis
Tianjin Medical University
Not applicable
200
Hefei, Qingdao, Tianjin
2022-03-01
Active, closed
Akeso
Phase 2
90
Tianjin
2022-02-20
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Phase 1/2
21
Tianjin
2022-02-16
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
30
Tianjin
2022-02-15
Recruiting
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
96
Beijing, Nanchang, Jinan, Chengdu, Tianjin, Hangzhou
2022-02-14
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
10
Tianjin
2022-01-25
Active, closed
Tianjin Medical University Cancer Institute and Hospital
Not applicable
150
Tianjin
2022-01-01
Active, closed
Shanghai Xinzhi BioMed Co., Ltd.
Phase 2/3
32
Hefei, Beijing, Guangzhou, Shenzhen, Tangshan, Zhengzhou, Taiyuan, Tianjin
2021-12-30
Recruiting
Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL
NCT05147467Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
DrugLisaftoclax
Ascentage Pharma Group Inc.
Phase 2
75
Guangzhou, Haikou, Zhengzhou, Wuhan, Suzhou, Nanchang, Tianjin, Hanzhou
2021-12-28
Active, closed
Sanofi
Phase 2
22
Beijing, Tianjin
2021-12-07
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Phase 3
342
Tianjin
2021-12-01
Recruiting
Dan Liu
Observational
30
Tianjin
2021-12-01
Recruiting
Pfizer
Phase 3
245
Guangzhou, Guiyang, Wuhan, Nanchang, Tianjin, Beijing
2021-11-17
Active, closed
argenx
Phase 3
173
Beijing, Bengbu, Huizhou, Shenzhen, Tianjin, Wuhan, Wuxi, Zhengzhou
2021-11-17
Recruiting
Guangzhou Excelmab Inc.
Phase 1/2
415
Zhengzhou, Jinan, Shanghai, Tianjin
2021-11-12
Recruiting
Triage of Patients With Acute Ischemic Stroke Due to Large Vessel Occlusions-2
NCT05659160Stroke, Acute Ischemic, Endovascular Procedures, Large Vessel Occlusion
Tianjin Huanhu Hospital
Observational
5,000
Tianjin
2021-11-01
Recruiting
Tianjin University of Traditional Chinese Medicine
Observational
20,000
Tianjin
2021-11-01
Active, closed
Hoffmann-La Roche
Phase 3
478
Beijing, Changchun, Guangzhou, Harbin, Nanchang, Nanjing, Shanghai, Tianjin
2021-10-27
Active, closed
Merck Sharp & Dohme LLC
Phase 1
45
Beijing, Guangzhou, Nanjing, Tianjin, Hangzhou
2021-10-13
Recruiting
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
NCT05006716B-cell Malignancy, Marginal Zone Lymphoma, Follicular Lymphoma, Non-Hodgkin Lymphoma
DrugTacabrutideg
BeOne Medicines
Phase 1/2
689
Beijing, Guangzhou, Zhengzhou, Yichang, Shanghai, Tianjin, Wenzhou
2021-09-13
Active, closed
AstraZeneca
Phase 3
98
Beijing, Ganzhou, Guangzhou, Jinan, Shenyang, Tianjin, Zhengzhou
2021-09-12
Recruiting
Avatrombopag in the Treatment of Adult Immune Thrombocytopenia With Autoantibodies
NCT04993885Immune Thrombocytopenia, Autoantibodies, Evan Syndrome, Connective Tissue Diseases
DrugAvatrombopag
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
52
Tianjin
2021-09-01
Active, closed
Novartis Pharmaceuticals
Phase 3
208
Beijing, Tianjin
2021-07-27
By invitation
UCB Biopharma SRL
Phase 3
760
Beijing, Changchun, Guangzhou, Guilin, Shanghai, Shantou, Suzhou, Tianjin
2021-07-27
Active, closed
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2
45
Hefei, Guangzhou, Nanning, Shijiazhuang, Zhengzhou, Wuhan, Suzhou, Tianjin
2021-06-25
Active, closed
Novartis Pharmaceuticals
Phase 3
1,144
Nanjing, Xian, Chengdu, Beijing, Guangzhou, Shanghai, Tianjin
2021-06-09
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Observational
1,000
Tianjin
2021-06-01
Recruiting
Jacobio Pharmaceuticals Co., Ltd.
Phase 1/2
152
Tianjin
2021-05-07
Active, closed
Hoffmann-La Roche
Phase 3
1,188
Chengdu, Chongqing, Guangzhou, Harbin, Shanghai, Tianjin, Wuhan, Xi'an
2021-05-04
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Phase 2
124
Tianjin
2021-05
Active, closed
Hoffmann-La Roche
Phase 3
557
Changsha, Fuzhou, Guangzhou, Hefei, Nanjing, Shanghai, Shenyang, Tianjin
2021-04-26
Active, closed
Takeda
Phase 3
77
Beijing, Wuhan, Suzhou, Tianjin
2021-04-14
Active, closed
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
687
Chongqing, Nanjin, Guiyang, Shanghai, Tianjin
2021-04-01
Active, closed
Tianjin Medical University Cancer Institute and Hospital
Phase 2
156
Tianjin
2021-03-31
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Phase 4
934
Tianjin
2021-03-25
Active, closed
Hoffmann-La Roche
Phase 3
51
Wuhan, Chengdu, Guangzhou, Tianjin
2021-03-17
Recruiting
Gene Therapy for Chinese Hemophilia A
NCT04728841Hemophilia A, Gene Therapy
Institute of Hematology & Blood Diseases Hospital, China
Not applicable
12
Tianjin
2021-03-04
Recruiting
China Monogenic Diabetes Registry
NCT07492004Neonatal Diabetes, Monogenic Diabetes, Maturity Onset Diabetes of the Young
Tianjin Medical University General Hospital
Observational
5,000
Tianjin
2021-02-28
Active, closed
Hoffmann-La Roche
Phase 3
270
Beijing, Guangzhou, Harbin, Shanghai, Tianjin, Wuhan, Zhejiang, Zhengzhou
2021-02-23
Recruiting
Janssen Research & Development, LLC
Phase 2
510
Beijing, Guangzhou, Hangzhou, Suzhou, Tianjin, Xi'an
2021-02-01
Recruiting
Tianjin Eye Hospital
Not applicable
40
Tianjin
2021-01-30
Active, closed
Hoffmann-La Roche
Phase 2
920
Beijing, Chengdu, Shanghai, Tianjin, Xi'an
2021-01-18
Active, closed
Shanghai Ming Ju Biotechnology Co., Ltd.
Phase 2
59
Beijing, Fuzhou, Guanzhou, Zhengzhou, Nanjing, Shanghai, Tianjin, Hangzhou
2021-01-13
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Not applicable
950
Tianjin
2021-01-01
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
6,642
Hefei, Zhoukou, Tai’an, Tianjin
2021-01-01
Recruiting
Eltrombopag for Chemotherapy-induced Thrombocytopenia
NCT04600960Chemotherapy-induced Thrombocytopenia, Eltrombopag
DrugEltrombopag
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
50
Tianjin
2020-12-31
Recruiting
National Longitudinal Cohort of Hematological Diseases
NCT04645199Multiple Myeloma, Acute Myeloid Leukemia, Hemophilia, Hemophilia A
Institute of Hematology & Blood Diseases Hospital, China
Observational
2,300
Tianjin
2020-12-01
Active, closed
Hoffmann-La Roche
Phase 2
303
Changchun, Guangzhou, Linyi, Nanchang, Shanghai, Tianjin, Wuhan, Xi'an
2020-11-27
Active, closed
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
47
Hefei, Beijing, Chongqing, Guangzhou, Changsha, Shanghai, Tianjin, Hangzhou
2020-11-04
Active, closed
Myasthenia Gravis Inebilizumab Trial
NCT04524273Myasthenia Gravis
DrugInebilizumab
Amgen
Phase 3
238
Beijing, Guiyang, Hunan, Jinan, Shanghai, Suzhou, Tianjin, Xi'an
2020-10-15
Active, closed
Ruihua Wei
Observational
3,000
Tianjin
2020-09-28
Active, closed
Janssen Research & Development, LLC
Phase 2
194
Beijing, Chengdu, Guangzhou, Hangzhou, Shanghai, Shenyang, Tianjin, Xi'an
2020-09-17
Active, closed
PF-07104091 as a Single Agent and in Combination Therapy
NCT04553133Small Cell Lung Cancer, Ovarian Cancer, Breast Cancer
DrugsPF-07104091·Palbociclib·Letrozole·Fulvestrant
Pfizer
Phase 2
157
Shanghai, Tianjin
2020-09-16
Active, closed
A Phase 1 Study of TRS005 in Patients With R/R CD20-positive B-NHL.
NCT05395533CD20-positive B-cell Non-Hodgkin Lymphoma
DrugTRS005
Zhejiang Teruisi Pharmaceutical Inc.
Phase 1
147
Beijing, Guangzhou, Zhengzhou, Suzhou, Tianjin
2020-09-08
Recruiting
Prostate Specific Membrane Antigen PET/CT Imaging in PSMA-Related Disease Patients
NCT06690970PSMA-related Disease, Prostate Cancer, Positron Emission Tomography, Metastasis
Tianjin Medical University
Observational
500
Hefei, Qingdao, Tianjin
2020-09-01
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Phase 4
224
Tianjin
2020-08-10
Recruiting
InxMed (Shanghai) Co., Ltd.
Phase 1/2
150
Anyang, Beijing, Changsha, Fuzhou, Hangzhou, Tianjin, Zhengzhou
2020-07-27
Active, closed
AstraZeneca
Phase 3
134
Chengdu, Shanghai, Tianjin, Xiamen, Zhengzhou
2020-07-20
Active, closed
GlaxoSmithKline
Phase 3
242
Beijing, Changchun, Chongqing, Guangzhou, Nanchang, Nanjing, Shanghai, Tianjin
2020-07-14
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
50
Tianjin
2020-07-08
Active, closed
Actelion
Phase 3
935
Beijing, Changsha, Chengdu, Chongqing, Guangzhou, Shanghai, Shenyang, Tianjin
2020-06-30
Active, closed
Sanofi
Phase 3
337
Hangzhou, Nanchang, Shanghai, Shenyang, Tianjin
2020-06-16
By invitation
Tianjin Medical University Eye Hospital
Observational
100,000
Tianjin
2020-06-01
Active, closed
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
61
Tianjin
2020-06-01
Active, closed
GlaxoSmithKline
Phase 3
325
Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Nanchang, Shenzhen, Tianjin
2020-04-02
Active, closed
Eli Lilly and Company
Phase 2
77
Beijing, Guangzhou, Changsha, Changchun, Jinan, Shanghai, Tianjin, Hangzhou
2020-03-16
Active, closed
Xynomic Pharmaceuticals, Inc.
Phase 1/2
12
Beijing, Hangzhou, Tianjin, Xuzhou
2020-01-08
Active, closed
Regeneron Pharmaceuticals
Phase 2
515
Beijing, Tianjin, Chongqing, Guangzhou, Harbin, Zhengzhou, Wuhan, Suzhou
2019-11-13
Recruiting
A Clinical Trial of TQB3455 Tablets in Patients With Hematological Malignancies
NCT06550713Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
DrugAzacitidine
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1
100
Beijing, Shijiazhuang, Harbin, Shanghai, Chengdu, Tianjin
2019-10-22
Active, closed
SyncAV Post-Market Trial
NCT04100148Congestive Heart Failure
Abbott Medical Devices
Not applicable
1,686
Tianjin, Xi'an, Hangzhou
2019-10-03
Recruiting
Shanghai Chest Hospital
Phase 3
176
Nanchang, Shanghai, Tianjin
2019-09-01
Recruiting
Dan Liu
Observational
70
Tianjin
2019-09-01
Recruiting
CooperVision International Limited (CVIL)
Not applicable
250
Shanghai, Tianjin, Wenzhou
2019-08-29
Recruiting
A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
NCT04064060Myelodysplastic Syndromes (MDS), Beta-thalassemia, Myeloproliferative Neoplasm(MPN)-Associated Myelofibrosis
DrugLuspatercept
Celgene
Phase 3
665
Beijing, Guangzhou, Shanghai, Chengdu, Tianjin, Hangzhou
2019-08-12
Active, closed
Quantitative Flow Ratio (QFR) Guided Coronary Artery Bypass Grafting for Patients Undergoing Primary Valve Surgery With Concomitant Coronary Artery Disease
NCT03977129Primary Valvular Heart Disease With Comorbid Coronary Artery Disease, Planned to Undergo Elective On-pump Valve Surgery Due to Primary Mitral and/or Aortic Valvular Heart Disease
Ruijin Hospital
Not applicable
792
Hefei, Fuzhou, Zhengzhou, Changsha, Jinan, Qingdao, Shanghai, Tianjin
2019-08-04
Active, closed
Decreasing Risk of Psychosis by Sulforaphane (DROPS Trial)
NCT03932136Clinical High Risk Syndrome of Psychosis
Shanghai Jiao Tong University School of Medicine
Phase 3
300
Guangzhou, Zhengzhou, Changsha, Suzhou, Shanghai, Shenzhen, Tianjin
2019-07-14
Active, closed
Ascentage Pharma Group Inc.
Phase 1
74
Hefei, Zhengzhou, Wuhan, Tianjin, Hangzhou
2019-06-03
By invitation
Tianjin Huanhu Hospital
Observational
236
Tianjin
2019-06-01
Recruiting
Tianjin Huanhu Hospital
Observational
1,000
Tianjin
2019-06-01
Active, closed
Celgene
Phase 1/2
438
Beijing, Guangzhou, Zhengzhou, Wuhan, Shenyang, Shanghai, Tianjin
2019-05-20
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
50
Tianjin
2019-05-15
Recruiting
Chinese University of Hong Kong
Phase 3
1,734
Xi'an, Shanghai, Tianjin, Hangzhou
2019-03-21
By invitation
Tianjin Medical University Cancer Institute and Hospital
Not applicable
1,300
Tianjin
2019-02-15
Recruiting
Glucagon-like Peptide-1 Receptor PET/CT in GLP-1R Related Disease
NCT06725693GLP1-R-related Disease, Tumor, Insulinoma, Positron Emission Tomography
Tianjin Medical University
Observational
500
Hefei, Qingdao, Tianjin
2019-02-01
Recruiting
Somatostatin Receptor PET/CT in SSTR-Related Disease Patients
NCT06690957SSTR-related Disease, Tumor, Positron Emission Tomography, Metastasis
Tianjin Medical University
Observational
500
Hefei, Qingdao, Tianjin
2019-02-01
By invitation
Chiyi Chen
Observational
100
Tianjin
2019-01-01
Active, closed
Tianjin Medical University Cancer Institute and Hospital
Observational
800
Tianjin
2019-01-01
Recruiting
Translocator Protein PET/CT in Various TSPO-Related Disease
NCT06725719Neuroinflammation, Stroke, Neurodegenerative Diseases
Tianjin Medical University
Observational
200
Hefei, Qingdao, Tianjin
2018-11-01
Active, closed
A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia
NCT03589326Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)
DrugsPonatinib·Imatinib·Cytarabine·Methotrexate
Takeda
Phase 3
245
Zhengzhou, Suzhou, Changchun, Hangzhou, Tianjin
2018-10-04
Recruiting
Tau PET/CT in Various Tau-Related Disease Patients
NCT06690983Tauopathies, Neurodegenerative Diseases, Neurodegeneration
Tianjin Medical University
Observational
500
Hefei, Qingdao, Tianjin
2018-08-01
Active, closed
Merck Sharp & Dohme LLC
Phase 3
797
Tianjin, Beijing, Guangzhou, Changsha, Shanghai, Xi’an, Hangzhou, Ningbo
2018-04-24
Active, closed
AbbVie
Phase 3
1,336
Guangzhou, Shijiazhuang, Wuhan, Changsha, Nanchang, Shanghai, Chengdu, Tianjin
2018-04-09
Recruiting
Randomization of Single vs Multiple Arterial Grafts
NCT03217006Coronary Artery Disease, Heart Diseases
Weill Medical College of Cornell University
Not applicable
4,300
Beijing, Changchun, Shanghai, Taiwan, Tianjin
2018-01-07
Not yet open
Tianjin Medical University Cancer Institute and Hospital
Not applicable
120
Tianjin
2018-01-01
Active, closed
Tianjin Medical University Second Hospital
Observational
190
Tianjin
2018-01-01
Active, closed
Assessment of IOP After Corneal Refractive Surgery Based on AI
NCT07544615Myopia, Myopia; Astigmatism, Refractive Surgery, Intraocular Pressure Changes
Tianjin Eye Hospital
Observational
10,030
Tianjin
2018-01-01
Recruiting
Triage of Patients Presenting Beyond 24 Hours With Acute Ischemic Stroke Due to Large Vessel Occlusions (TRACK-LVO Late)
NCT06200753Endovascular Thrombectomy, Large Vessel Occlusion, Acute Ischemic Stroke
Tianjin Huanhu Hospital
Observational
1,000
Tianjin
2018-01-01
Not yet open
Tianjin Medical University Cancer Institute and Hospital
Not applicable
158
Tianjin
2017-12-20
Active, closed
Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation
NCT03173248Newly Diagnosed Acute Myeloid Leukemia (AML), Untreated AML, AML Arising From Myelodysplastic Syndrome (MDS), Leukemia, Myeloid, Acute
DrugsIvosidenib·Azacitidine
Institut de Recherches Internationales Servier
Phase 3
146
Zhengzhou, Chengdu, Beijing, Guangzhou, Hangzhou, Tianjin
2017-06-26
Active, closed
Institute of Hematology & Blood Diseases Hospital, China
Phase 1/2
250
Tianjin
2017-02-08
By invitation
Institute of Hematology & Blood Diseases Hospital, China
Phase 1/2
80
Tianjin
2017-02-08
Active, closed
Institute of Hematology & Blood Diseases Hospital, China
Phase 3
1,100
Tianjin
2017-02-08
Recruiting
CCTA Improves Clinical Management of Stable Chest Pain
NCT04691037Coronary Computed Tomography Angiography, Stable Chest Pain, Optimal Medical Therapy, Invasive Coronary Angiography
Tianjin Chest Hospital
Observational
50,000
Beijing, Langfang, Tianjin
2016-01-01
Active, closed
Bayer
Phase 1/2
154
Beijing, Guangzhou, Tianjin
2015-12-16
Recruiting
China Registry for Genetic / Metabolic Liver Diseases
NCT03131427Genetic/Metabolic Liver Diseases
Beijing Friendship Hospital
Observational
20,000
Beijing, Guangzhou, Shijiazhuang, Zhengzhou, Shanghai, Chengdu, Tianjin, Ürümqi
2015-06-13
Recruiting
Amino Acid Transporter System PET/CT Imaging in AATS-Related Diseases
NCT07379463Amino-Acid Transport Disorder, Primary Hyperparathyroidism, Glioma
Tianjin Medical University
Observational
500
Hefei, Qingdao, Tianjin
2013-08-29
Recruiting
Hydroxyephedrine PET/CT in Sympathetic Nervous System Disease
NCT06951984Sympathetic Nervous System Diseases, Sympathetic Nervous Structure Injury, Sympathetic Nerve Injury
Tianjin Medical University
Observational
500
Tianjin
2013-03-01
Recruiting
Beta Amyloid PET/CT in Various Aβ-Related Disease
NCT06725706Amyloid, Beta-Amyloid, Neurodegenerative Diseases
Tianjin Medical University
Observational
500
Hefei, Beijing, Qingdao, Tianjin
2012-09-01
By invitation
Texas Scottish Rite Hospital for Children
Observational
1,500
Tianjin
2012-08
Recruiting
Peking Union Medical College
Observational
2,000
Beijing, Chongqing, Guangzhou, Nanning, Shijiazhuang, Tianjin, Wuhan, Nanjing
2005-01
Recruiting
National Longitudinal Cohort of Hematological Diseases- Autoimmune Hemolytic Anemia
NCT07019038AIHA - Warm Autoimmune Hemolytic Anemia, AIHA - Cold Autoimmune Hemolytic Anemia, Autoimmune Hemolytic Anemia Mixed Type
Institute of Hematology & Blood Diseases Hospital, China
Observational
9,999
Tianjin
2001-01-01
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Observational
9,999
Tianjin
2000-01-01
Rows per page Showing 501–937 of 937
Previous 1 2
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 11 November 2026. https://priyalifescience.com/clinical-trials-china/city/tianjin?page=2

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,224 studies in total at the last sync on 11 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 937 of those studies with a site in Tianjin.

How many clinical trials are recruiting in Tianjin?

594 of the 937 studies on this page are recruiting new participants as of the 11 Nov 2026, 03:17 UTC sync. A further 159 have not yet opened recruitment, 158 are active but closed to new participants, and 26 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.